ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ALN-6400

A development code.

Its studies are mostly in von Willebrand Diseases · Telangiectasia, Hereditary Hemorrhagic, led by Alnylam Pharmaceuticals.

Furthest: phase 2, since Oct 24, 20242 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alnylam Pharmaceuticals22 open or runningphase 2since Oct 24, 2024Oct 24, 2024Jun 30, 2027phase 2 · NCT07575308

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 24, 2024First study: phase 2 study in Telangiectasia, Hereditary HemorrhagicFirst studyNCT06659640 · 89 enrolled · United States, Australia, Canada and more
  2. May 4, 2026Phase 2 study in von Willebrand DiseasesNCT07575308 · 24 planned · United States, Germany, Netherlands and more

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in von Willebrand DiseasesNCT07575308
  2. Jan 5, 2028Primary completion: phase 2 study in Telangiectasia, Hereditary HemorrhagicNCT06659640

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07575308von Willebrand Diseases · United States, Germany, Netherlands and more2RecruitingJun 30, 202724
NCT06659640Telangiectasia, Hereditary Hemorrhagic · United States, Australia, Canada and more2Active, not recruitingJan 5, 202889

How it is read

Names in the registry

  • “ALN-6400”, 2 entries

Codes read as this program: ALN6400.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.